Regeneron Pharmaceuticals Inc. (REGN)

Business: Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

IPO Date: 02-Apr-1991

Founder, Pres, CEO & Director: Dr. Leonard S. Schleifer M.D., Ph.D.

Scientific Founder, Pres, Chief Scientific Officer & Director: Dr. George D. Yancopoulos M.D., Ph.D.

Listing: NASDAQ: REGN

Country: United States

Headquarters: Tarrytown, NY

Website: https://www.regeneron.com

Market cap: $69,209.18 Mln

Revenue (TTM): $16,508.10 Mln

Earnings (TTM): $7,933.60 Mln

Cash: $7,050.60 Mln

Total Debt: $2,700.40 Mln

Insider's Holding: 2.69%

Liquidity: Low

52 Week range: $538.01 - 747.42

Shares outstanding: 108,028,000

10 Years Aggregate:

• CFO: $19,687.98 Mln
• EBITDA: $26,340.57 Mln
• Net Profit: $20,401.49 Mln